Mandate

Vinge advised IBT on its Nasdaq Stockholm main market listing

September 10, 2018 Capital Markets and Public M&A

The shares of Infant Bacterial Therapeutics AB (publ) have been admitted to trading on the main market of Nasdaq Stockholm (Mid Cap).

 Vinge advised IBT.

The Vinge team included Erik Sjöman, Christian Lindhé and Astrid Karlsson..
 

Related

Vinge advises in connection with data center provider EcoDataCenter’s issue of SEK 500 million senior unsecured bonds

Vinge has advised ABG Sundal Collier in connection with EcoDC Holding AB (publ)'s issue of SEK 500 million senior unsecured bonds, within a framework of up to SEK 2 billion.
November 28, 2025

Vinge has advised Northmill Group AB in connection with the issuance of tier 2 capital bonds (T2)

Vinge has advised Northmill Group AB in connection with its successful issuance of SEK 100 million tier 2 capital bonds (T2) with a floating rate interest of 3-month STIBOR + 650 basis points.
November 26, 2025

Vinge has advised Fortinova Fastigheter in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Fortinova Fastigheter AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm. The prospectus was published on 12 November 2025 and the trading on Nasdaq Stockholm commenced on 19 November 2025, five years to the day since the first listing.
November 19, 2025